<DOC>
	<DOCNO>NCT01608243</DOCNO>
	<brief_summary>The purpose study investigate safety different dos sublingual tablet house dust mite allergen extract adult house dust mite-associated allergic asthma .</brief_summary>
	<brief_title>Safety Study Sublingual Immunotherapy Tablets House Dust Mite Allergen Extracts</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Written inform consent . Male female patient 18 50 year . Diagnosed asthma medical history consistent HDMinduced allergic asthma . Positive SPT House Dust Mites ( HDM ) HDMspecific IgE serum value ≥ 0.7 kU/L . Stable asthma treatment . Spirometry best FEV1 &gt; 70 % predict value . Spirometry reversibility FEV1 ≥ 12 % ≥ 200 mL . Asthma Control Test™ ( ACT ) score ≥ 20 . Current smoker former smoker &gt; 10 pack/year history . Cosensitisation allergen possibly lead clinically relevant respiratory allergy likely significantly change symptom patient throughout treatment period . Patient past current disease , judge Investigator , may affect patient 's participation outcome study . Patient oral condition could confound safety assessment plan dental extraction study . Female patient pregnant breastfeeding/lactating . Female patient childbearing potential use medically accept contraceptive method . Patient treat betablockers , tricyclic antidepressant monoamine oxidase inhibitor ( MAOIs ) . Patient receive allergen immunotherapy HDM last 10 year . Ongoing treatment immunotherapy another allergen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>